PLIANT THERAPEUTICS, INC. (PLRX)
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
📈 **POSITIVE** • Low confidence analysis (54%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (78%) **Content type:** Clinical